SHARE

GSK raises outlook

The pharmaceutical company has upped its 2031 sales outlook to over £40bn, up from £38bn. Total 2024 sales were 31.4bn which was an increase of 3%, while core operating profit rose 11%. CEO Emma Walmsley categorised it as a “year of excellent performance”.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.